S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.17 (+0.76%)
MSFT   326.10 (+0.84%)
META   265.64 (+0.77%)
GOOGL   122.84 (+0.28%)
AMZN   125.07 (+3.17%)
TSLA   230.93 (+2.83%)
NVDA   384.40 (+2.58%)
NIO   7.67 (-1.16%)
BABA   86.80 (+1.78%)
AMD   120.02 (+1.86%)
T   15.95 (-0.93%)
F   13.51 (-0.59%)
MU   64.30 (-4.12%)
CGC   0.71 (-2.37%)
GE   106.66 (+0.55%)
DIS   92.23 (-0.31%)
AMC   4.61 (-2.54%)
PFE   39.01 (+0.31%)
PYPL   64.59 (+0.86%)
NFLX   405.00 (+1.31%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.17 (+0.76%)
MSFT   326.10 (+0.84%)
META   265.64 (+0.77%)
GOOGL   122.84 (+0.28%)
AMZN   125.07 (+3.17%)
TSLA   230.93 (+2.83%)
NVDA   384.40 (+2.58%)
NIO   7.67 (-1.16%)
BABA   86.80 (+1.78%)
AMD   120.02 (+1.86%)
T   15.95 (-0.93%)
F   13.51 (-0.59%)
MU   64.30 (-4.12%)
CGC   0.71 (-2.37%)
GE   106.66 (+0.55%)
DIS   92.23 (-0.31%)
AMC   4.61 (-2.54%)
PFE   39.01 (+0.31%)
PYPL   64.59 (+0.86%)
NFLX   405.00 (+1.31%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.17 (+0.76%)
MSFT   326.10 (+0.84%)
META   265.64 (+0.77%)
GOOGL   122.84 (+0.28%)
AMZN   125.07 (+3.17%)
TSLA   230.93 (+2.83%)
NVDA   384.40 (+2.58%)
NIO   7.67 (-1.16%)
BABA   86.80 (+1.78%)
AMD   120.02 (+1.86%)
T   15.95 (-0.93%)
F   13.51 (-0.59%)
MU   64.30 (-4.12%)
CGC   0.71 (-2.37%)
GE   106.66 (+0.55%)
DIS   92.23 (-0.31%)
AMC   4.61 (-2.54%)
PFE   39.01 (+0.31%)
PYPL   64.59 (+0.86%)
NFLX   405.00 (+1.31%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.17 (+0.76%)
MSFT   326.10 (+0.84%)
META   265.64 (+0.77%)
GOOGL   122.84 (+0.28%)
AMZN   125.07 (+3.17%)
TSLA   230.93 (+2.83%)
NVDA   384.40 (+2.58%)
NIO   7.67 (-1.16%)
BABA   86.80 (+1.78%)
AMD   120.02 (+1.86%)
T   15.95 (-0.93%)
F   13.51 (-0.59%)
MU   64.30 (-4.12%)
CGC   0.71 (-2.37%)
GE   106.66 (+0.55%)
DIS   92.23 (-0.31%)
AMC   4.61 (-2.54%)
PFE   39.01 (+0.31%)
PYPL   64.59 (+0.86%)
NFLX   405.00 (+1.31%)
NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Competitors

$11.97
-0.01 (-0.08%)
(As of 11:03 AM ET)
Compare
Today's Range
$11.88
$12.13
50-Day Range
$11.50
$18.08
52-Week Range
$6.15
$22.11
Volume
322,202 shs
Average Volume
2.13 million shs
Market Capitalization
$1.27 billion
P/E Ratio
13.60
Dividend Yield
N/A
Price Target
$21.50

CPRX vs. SMMT, ARVN, LGND, BMEA, GPCR, CTIC, CRNX, OPK, PLRX, and IDYA

Should you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Summit Therapeutics (SMMT), Arvinas (ARVN), Ligand Pharmaceuticals (LGND), Biomea Fusion (BMEA), Structure Therapeutics (GPCR), CTI BioPharma (CTIC), Crinetics Pharmaceuticals (CRNX), OPKO Health (OPK), Pliant Therapeutics (PLRX), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical preparations" industry.

Catalyst Pharmaceuticals vs.

Summit Therapeutics (NASDAQ:SMMT) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

1.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Catalyst Pharmaceuticals shares are owned by institutional investors. 83.7% of Summit Therapeutics shares are owned by company insiders. Comparatively, 14.1% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Catalyst Pharmaceuticals received 185 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 74.88% of users gave Catalyst Pharmaceuticals an outperform vote while only 57.06% of users gave Summit Therapeutics an outperform vote.

CompanyUnderperformOutperform
Summit TherapeuticsOutperform Votes
283
57.06%
Underperform Votes
213
42.94%
Catalyst PharmaceuticalsOutperform Votes
468
74.88%
Underperform Votes
157
25.12%

Summit Therapeutics has a beta of -1.03, suggesting that its stock price is 203% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.

In the previous week, Catalyst Pharmaceuticals had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 9 mentions for Catalyst Pharmaceuticals and 3 mentions for Summit Therapeutics. Catalyst Pharmaceuticals' average media sentiment score of 0.53 beat Summit Therapeutics' score of 0.45 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Catalyst Pharmaceuticals
4 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Catalyst Pharmaceuticals has a consensus target price of $21.50, suggesting a potential upside of 79.47%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Summit Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Catalyst Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Catalyst Pharmaceuticals has a net margin of 38.76% compared to Summit Therapeutics' net margin of -1,012.41%. Catalyst Pharmaceuticals' return on equity of 34.72% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit Therapeutics -1,012.41% -70.92% -26.95%
Catalyst Pharmaceuticals 38.76% 34.72% 28.75%

Catalyst Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit Therapeutics$700 thousand1,873.77-$78.78 million-$1.81-1.04
Catalyst Pharmaceuticals$214.20 million5.93$83.08 million$0.8813.61

Summary

Catalyst Pharmaceuticals beats Summit Therapeutics on 16 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CPRX vs. The Competition

MetricCatalyst PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.27B$6.03B$4.56B$6.23B
Dividend YieldN/A2.61%2.37%6.48%
P/E Ratio13.6110.18147.2115.09
Price / Sales5.93338.043,455.0188.96
Price / Cash14.2418.9691.78104.89
Price / Book4.154.924.725.29
Net Income$83.08M$204.56M$118.18M$193.04M
7 Day Performance2.92%5.58%5.20%3.91%
1 Month Performance-31.03%4.38%4.71%5.38%
1 Year Performance72.13%15.25%11.64%1.73%

Catalyst Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMMT
Summit Therapeutics
1.3746 of 5 stars
$1.98
+6.5%
N/A+84.3%$1.30B$455,000.00-1.09105
ARVN
Arvinas
1.8915 of 5 stars
$23.54
+1.7%
$67.33
+186.0%
-46.4%$1.26B$131.40M-4.16280
LGND
Ligand Pharmaceuticals
2.6256 of 5 stars
$72.50
+2.1%
$112.25
+54.8%
-13.0%$1.25B$196.24M57.54154
BMEA
Biomea Fusion
1.436 of 5 stars
$38.24
+1.9%
$40.29
+5.3%
+470.0%$1.35BN/A-11.9151
GPCR
Structure Therapeutics
1.9603 of 5 stars
$32.70
+3.2%
$41.00
+25.4%
N/A$1.20BN/A0.00N/AHigh Trading Volume
CTIC
CTI BioPharma
2.0526 of 5 stars
$9.05
flat
$10.29
+13.7%
+69.6%$1.19B$75.77M-15.6022
CRNX
Crinetics Pharmaceuticals
2.1715 of 5 stars
$22.01
+1.1%
$45.50
+106.7%
+12.9%$1.19B$4.74M-6.71143
OPK
OPKO Health
2.2453 of 5 stars
$1.52
+4.8%
$4.13
+171.9%
-44.6%$1.17B$1.00B-4.004,196Analyst Upgrade
News Coverage
PLRX
Pliant Therapeutics
2.4025 of 5 stars
$23.67
+2.9%
$47.83
+102.1%
+243.1%$1.40B$9.69M-8.2891Positive News
IDYA
IDEAYA Biosciences
1.8151 of 5 stars
$24.45
+0.2%
$29.40
+20.2%
+100.3%$1.40B$50.93M-16.0981

Related Companies and Tools

This page (NASDAQ:CPRX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -